| Dr Emma Walker, DO | |
|
1326 Eisenhower Dr Bldg 2, Savannah, GA 31406-3928 | |
| (912) 354-6303 | |
| Not Available |
| Full Name | Dr Emma Walker |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 15 Years |
| Location | 1326 Eisenhower Dr Bldg 2, Savannah, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316375017 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 81327 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Candler Hospital | Savannah, GA | Hospital |
| St Joseph's Hospital - Savannah | Savannah, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sjc General Surgery Llc | 2668855776 | 6 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United States patent (No. 8,314,100), titled "1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives."
DreaMed Diabetes, developer of diabetes treatment and management solutions, announced today that it had signed an exclusive worldwide development and license agreement with Medtronic, the world's premier medical technology and services company, for the development and marketing of products incorporating DreaMed's MD-Logic Artificial Pancreas algorithm in Medtronic's insulin pumps.
The Tennesseean: "Healthways Inc. will return $28 million to Medicare's overseer under a settlement related to the company's participation in a pilot program to determine the effectiveness of its nurse-based health coaching for chronically ill seniors." The Centers for Medicare and Medicaid Services had paid the company $72 million for the pilot program, which ended two years ago, under the condition that it meet "specific targets for cost savings, health outcomes and patient satisfaction."
About one in four Americans has hypertension, a disease that elevates blood pressure and can lead to a host of serious problems including heart attacks and strokes.
A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.
› Verified 1 days ago
| Entity Name | Southcoast Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467451922 PECOS PAC ID: 9032013271 Enrollment ID: O20040109000192 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United States patent (No. 8,314,100), titled "1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives."
DreaMed Diabetes, developer of diabetes treatment and management solutions, announced today that it had signed an exclusive worldwide development and license agreement with Medtronic, the world's premier medical technology and services company, for the development and marketing of products incorporating DreaMed's MD-Logic Artificial Pancreas algorithm in Medtronic's insulin pumps.
The Tennesseean: "Healthways Inc. will return $28 million to Medicare's overseer under a settlement related to the company's participation in a pilot program to determine the effectiveness of its nurse-based health coaching for chronically ill seniors." The Centers for Medicare and Medicaid Services had paid the company $72 million for the pilot program, which ended two years ago, under the condition that it meet "specific targets for cost savings, health outcomes and patient satisfaction."
About one in four Americans has hypertension, a disease that elevates blood pressure and can lead to a host of serious problems including heart attacks and strokes.
A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.
› Verified 1 days ago
| Entity Name | Privia Medical Group Of Georgia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013313857 PECOS PAC ID: 4284951542 Enrollment ID: O20150325000983 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United States patent (No. 8,314,100), titled "1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives."
DreaMed Diabetes, developer of diabetes treatment and management solutions, announced today that it had signed an exclusive worldwide development and license agreement with Medtronic, the world's premier medical technology and services company, for the development and marketing of products incorporating DreaMed's MD-Logic Artificial Pancreas algorithm in Medtronic's insulin pumps.
The Tennesseean: "Healthways Inc. will return $28 million to Medicare's overseer under a settlement related to the company's participation in a pilot program to determine the effectiveness of its nurse-based health coaching for chronically ill seniors." The Centers for Medicare and Medicaid Services had paid the company $72 million for the pilot program, which ended two years ago, under the condition that it meet "specific targets for cost savings, health outcomes and patient satisfaction."
About one in four Americans has hypertension, a disease that elevates blood pressure and can lead to a host of serious problems including heart attacks and strokes.
A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.
› Verified 1 days ago
| Entity Name | Sjc General Surgery Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124758966 PECOS PAC ID: 2668855776 Enrollment ID: O20220822002365 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United States patent (No. 8,314,100), titled "1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives."
DreaMed Diabetes, developer of diabetes treatment and management solutions, announced today that it had signed an exclusive worldwide development and license agreement with Medtronic, the world's premier medical technology and services company, for the development and marketing of products incorporating DreaMed's MD-Logic Artificial Pancreas algorithm in Medtronic's insulin pumps.
The Tennesseean: "Healthways Inc. will return $28 million to Medicare's overseer under a settlement related to the company's participation in a pilot program to determine the effectiveness of its nurse-based health coaching for chronically ill seniors." The Centers for Medicare and Medicaid Services had paid the company $72 million for the pilot program, which ended two years ago, under the condition that it meet "specific targets for cost savings, health outcomes and patient satisfaction."
About one in four Americans has hypertension, a disease that elevates blood pressure and can lead to a host of serious problems including heart attacks and strokes.
A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emma Walker, DO Po Box 15849, Savannah, GA 31416-2549 Ph: (912) 303-3552 | Dr Emma Walker, DO 1326 Eisenhower Dr Bldg 2, Savannah, GA 31406-3928 Ph: (912) 354-6303 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United States patent (No. 8,314,100), titled "1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives."
DreaMed Diabetes, developer of diabetes treatment and management solutions, announced today that it had signed an exclusive worldwide development and license agreement with Medtronic, the world's premier medical technology and services company, for the development and marketing of products incorporating DreaMed's MD-Logic Artificial Pancreas algorithm in Medtronic's insulin pumps.
The Tennesseean: "Healthways Inc. will return $28 million to Medicare's overseer under a settlement related to the company's participation in a pilot program to determine the effectiveness of its nurse-based health coaching for chronically ill seniors." The Centers for Medicare and Medicaid Services had paid the company $72 million for the pilot program, which ended two years ago, under the condition that it meet "specific targets for cost savings, health outcomes and patient satisfaction."
About one in four Americans has hypertension, a disease that elevates blood pressure and can lead to a host of serious problems including heart attacks and strokes.
A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.
› Verified 1 days ago
Catherine Ann Ronaghan, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 5353 Reynolds St Ste 107, Savannah, GA 31405 Phone: 912-819-7630 Fax: 912-819-5860 | |
Robert Joseph Kelly Jr., MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4700 Waters Avenue, 1st Floor Mus Bldg, Savannah, GA 31404 Phone: 912-350-8712 Fax: 912-350-8753 | |
Edward J Cohn Jr., M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 4750 Waters Ave, Suite 500, Savannah, GA 31404 Phone: 866-957-8346 Fax: 912-355-1414 | |
Davis Sungwhan Moon, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4750 Waters Ave Ste 500, Savannah, GA 31404 Phone: 912-352-8346 Fax: 912-355-5515 | |
David Helmar Smith, MD Surgery Medicare: Medicare Enrolled Practice Location: 5361 Reynolds St, Savannah, GA 31405 Phone: 912-355-8000 Fax: 912-355-8403 | |
Glenn N Carlos, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4700 Waters Ave Ste 403, Savannah, GA 31404 Phone: 912-273-1150 | |
Dr. Jeffrey Samuel Mandel, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1326 Eisenhower Dr Bldg 2, Savannah, GA 31406 Phone: 912-354-6303 Fax: 912-355-8655 |